Key points from article :
D.C.-based neurotechnology company Altoida Inc. has secured $14 million to advance a unique platform designed to detect Alzheimer’s disease and other neurodegenerative conditions earlier. Using a smart device, Altoida’s technology captures critical data about brain function, helping to identify early cognitive changes associated with these diseases. By leveraging artificial intelligence and augmented reality, the platform measures cognitive and functional biomarkers through tasks that test memory, motor skills, and spatial navigation, aiming to provide a non-invasive, accessible diagnostic tool.
The research, conducted in the United States, targets the pressing need for early and accessible Alzheimer’s diagnosis, especially as the population ages. Traditional diagnostic methods often detect neurodegenerative diseases too late for effective intervention. Altoida’s approach enables users to monitor their cognitive health from home, potentially leading to more proactive healthcare and lifestyle adjustments if early signs are detected. The platform’s user-friendly design could also improve patient compliance and make testing available to those with limited access to specialist healthcare facilities.
With this new funding, Altoida plans to refine its diagnostic technology and expand its reach, enabling more individuals to benefit from early disease detection. The platform’s non-invasive nature is particularly relevant to populations wary of clinical settings or invasive procedures, making it a promising option for routine cognitive health monitoring. Altoida’s innovative approach aligns with the trend toward personalized and preventive healthcare, providing a practical solution that could improve patients' quality of life and ease healthcare systems’ burdens.
The team behind Altoida includes experts in neuroscience, AI, and healthcare, driving the development of this platform with a strong focus on accessibility and reliability.
